Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth
Company Announcements

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

Kiromic Biopharma (KRBP) has released an update.

Kiromic BioPharma, Inc. has secured a financial boost by issuing a Senior Secured Convertible Promissory Note worth $2 million to an accredited investor, carrying a substantial 25% annual interest rate. This note will mature in a year, with the option for the investor to convert the debt into company stock at a set price, subject to ownership limits. The debt, secured by the company’s assets and intellectual property, is prioritized over other obligations and allows for additional borrowing, signaling a strategic move to strengthen the company’s financial position amidst its growth trajectory.

For further insights into KRBP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyKiromic BioPharma gives follow-up results for 1st patient in Deltacel trial
TheFlyKiromic BioPharma’s Deltacel receives FDA fast track designation
TheFlyKiromic BioPharma reports interim results from Deltacel-01 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App